Galapagos follows positive RA data with $300M round

On the heels of positive Phase III data for rheumatoid arthritis therapy filgotinib, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) raised $300 million through the sale of 2.6 million ADSs at $116.50 on NASDAQ. Morgan Stanley, Citigroup, Kempen & Co., Nomura

Read the full 388 word article

User Sign In